Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Molecular events in bronchogenic carcinoma and their implications for therapy
Autore:
Toloza, EM; Roth, JA; Swisher, SG;
Indirizzi:
Univ Texas, MD Anderson Canc Ctr, Div Thorac & Cardiovasc Surg, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 & Cardiovasc Surg, Houston, TX 77030 USA
Titolo Testata:
SEMINARS IN SURGICAL ONCOLOGY
fascicolo: 2, volume: 18, anno: 2000,
pagine: 91 - 99
SICI:
8756-0437(200003)18:2<91:MEIBCA>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
LUNG-CANCER PATIENTS; WILD-TYPE P53; BRONCHIAL EPITHELIUM; GENE-TRANSFER; RECOMBINANT ADENOVIRUS; IONIZING-RADIATION; ANTISENSE RNA; GROWTH-FACTOR; CELLS; EXPRESSION;
Keywords:
bronchogenic carcinoma; lung neoplasms; adenocarcinoma; squamous cell carcinoma; lymphatic metastasis; neoplasm invasiveness; tumor suppressor genes; apoptosis; oncogenes; prognosis; survival rate; mucosa; sputum; chromosome aberrations; risk factors; smoking;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
52
Recensione:
Indirizzi per estratti:
Indirizzo: Toloza, EM Univ Texas, MD Anderson Canc Ctr, Div Thorac & Cardiovasc Surg,1515 Holcombe Blvd,Box 109, Houston, TX 77030 USA Univ Texas 1515 HolcombeBlvd,Box 109 Houston TX USA 77030 USA
Citazione:
E.M. Toloza et al., "Molecular events in bronchogenic carcinoma and their implications for therapy", SEM SURG ON, 18(2), 2000, pp. 91-99

Abstract

Lung cancer patients suffer a 15% overall survival despite advances in chemotherapy, radiation therapy and surgery. This unacceptably low survival rate is due to the usual finding of advanced disease at diagnosis. Detecting preneoplastic lesions and determining which invasive lesions are prone to metastasize or recur can be formidable tasks. Understanding the molecular events that occur during the multistep process of bronchogenic carcinogenesismay make these tasks more surmountable. Approaches leading to identification of patients susceptible to cancer formation include detection of poor metabolizers of carcinogens, those unable to repair genetic alterations, those with activated oncogenes or inactivated tumor suppressor genes, and thoseat risk of poor outcomes. Detection may be achieved at the cellular, chromosomal, genetic, or protein level. Novel therapies can then be developed that prevent tumor initiation into and promotion through the multistep carcinogenesis pathway, conversion from preneoplastic into invasive malignancies,and progression into metastasis or recurrences. Therapeutic success of chemoprevention can be followed by changes in molecular marker levels. Blockade of activated tumor-promoting oncogenes or replacement of inactivated tumor-suppressing or apoptosis-promoting genes can be achieved by gene therapy. Development of these novel molecular diagnostic and therapeutic strategiescould result in prevention of cancer formation or at least prolongation ofdisease-free survival. (C) 2000 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 04:37:33